Abstract
Purpose
To evaluate the diagnostic potential of DW-MRI relative parameters for differentiation of rectal cancers with different Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation status.
Methods
Fifty-one patients with rectal cancer underwent diffusion-weighted MR imaging with eight b values. ADCs (including Max-ADC, Min-ADC and Mean-ADC) and IVIM parameters (D, pure diffusion; f, perfusion fraction; D*, pseudodiffusion coefficient) were respectively calculated by mono- and bi-exponential analysis. Patients were stratified into two groups: KRAS wild type and mutant. The DW-MRI-derived parameters between the KRAS wild-type group and KRAS mutant group were compared using the Mann-Whitney U test. Receiver-operating characteristic (ROC) analysis of discrimination between KRAS wild-type and KRAS mutant rectal cancer was performed for the DW-MRI-derived parameters.
Results
Max-ADC, Mean-ADC and D values were significantly lower in the KRAS mutant group than in the KRAS wild-type group, whereas a higher D* value was demonstrated in the KRAS mutant group. According to the ROC curve, Mean-ADC and D* values showed moderate diagnostic significance with the AUC values of 0.756 and 0.710, respectively. The cut-off values for Mean-ADC and D* were 1.43 × 10-3mm2/s and 26.58 × 10-3mm2/s, respectively.
Conclusion
Rectal cancers had distinctive diffusion/perfusion characteristics in different KRAS mutation statuses. The DW-MRI-derived parameters, specifically Mean-ADC and D*, show a moderate diagnostic significance for KRAS status.
Key Points
• Rectal cancers with different KRAS mutation statuses demonstrated distinctive diffusion/perfusion characteristics.
• Max-ADC, Mean-ADC and D values were lower in the KRAS mutant group.
• A higher D* value was demonstrated in the KRAS mutant group.
• IVIM-DW MRI may potentially help preoperative KRAS mutant status prediction.
Similar content being viewed by others
Abbreviations
- ADC:
-
Apparent diffusion coefficient
- CRC:
-
Colorectal cancer
- D:
-
Diffusion coefficient
- D*:
-
Pseudo-diffusion coefficient
- DWI:
-
Diffusion-weighted imaging
- EGFR:
-
Epidermal growth factor receptor
- f:
-
Perfusion fraction
- IVIM:
-
Intravoxel incoherent motion
- KRAS:
-
Kirsten rat sarcoma viral oncogene homologue
- MRI:
-
Magnetic resonance imaging
- NCCN:
-
National Comprehensive Cancer Network
- ROI:
-
Region of interest
- ROC:
-
Receiver-operating characteristic
- TE:
-
Echo time
- TR:
-
Repetition time
- TSE:
-
Turbo spin echo
References
Weizt J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW (2005) Colorectal cancer. Lancet 365:153–165
Migliore L, Migheli F, Spisni R, Coppedè F (2011) Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011:792362
Brand TM, Wheeler DL (2012) KRAS mutant colorectal tumors: past and present. Small GTPases 3:34–39
Wang HL, Lopategui J, Amin MB, Patterson SD (2010) KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine. Adv Anat Pathol 17:23–32
NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (2016)-NCCN Evidence Blocks. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Published February 8, 2016.
NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (2016)\ National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Published November 4, 2015.
Bae H, Yoshida S, Matsuoka Y et al (2014) Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer. Int Urol Nephrol 46:555–561
Higano S, Yun X, Kumabe T et al (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241:839–846
Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RG (2012) Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 35:1365–1371
Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497–505
Sun H, Xu Y, Xu Q et al (2017) Rectal cancer: Short-term reproducibility of intravoxel incoherent motion parameters in 3.0T magnetic resonance imaging. Medicine (Baltimore) 96:e6866
Nougaret S, Vargas HA, Lakhman Y et al (2016) Intravoxel incoherent motion-derived histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses. Radiology 280:446–454
Xiao-ping Y, Jing H, Fei-ping L et al (2016) Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma. J Magn Reson Imaging 43:1179–1190
Jenkinson MD, du Plessis DG, Smith TS, Brodbelt AR, Joyce KA, Walker C (2010) Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype. J Neuro oncol 96:385–392
Guiu B, Petit JM, Capitan V et al (2012) Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study. Radiology 265:96–103
Sun Y, Tong T, Cai S, Bi R, Xin C, Gu Y (2014) Apparent Diffusion Coefficient (ADC) Value: a potential imaging biomarker that reflects the biological features of rectal cancer. Plos One 9:e109371
Lai V, Li X, Lee VH et al (2014) Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging. Eur Radiol 24:176–183
Jung SH, Heo SH, Kim JW et al (2012) Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging. J Magn Reson Imaging 35:110–116
Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ (1997) Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79:1106–1113
Kobayashi M, Watanabe H, Ajioka Y, Honma T, Asakura H (1996) Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells. Hum Pathol 27:1042–1049
Shigenori K, Miho K, Shuhei T et al (2015) Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol 21:1275–1283
Andreyev HJ, Norman AR, Cunningham D et al (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85:692–696
Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466–474
Downward J (2003) Targeting RAS signaling pathways in the cancer therapy. Nat Rev Cancer 3:11–322
Bazan V, Agnese V, Corsale S et al (2005) Specific TP53 and/ or K-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol 16:iv50–iv55
Li W, Qiu T, Zhi W et al (2015) Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer 15:340
Smith G, Carey FA, Beattie J et al (2002) Proc Natl Acad Sci USA 99:9433–9438. Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer
Coppedè F, Lopomo A, Spisni R, Migliore L (2014) Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20:943–956
Xu Q, Xu AT, Zhu MM, Tong JL, Xu XT, Ran ZH (2013) Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis. J Dig Dis 14:409–416
Funding
This work was supported by grants from the National Natural Science Foundation of China (no. 81501469) and the Health Industry Special Scientific Research Project of the National Health and Family Planning Commission of the People’s Republic of China (no. 201402019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Dr. Hongliang Sun.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise.
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was waived in this study.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• retrospective
• observational
• performed at one institution
Rights and permissions
About this article
Cite this article
Xu, Y., Xu, Q., Sun, H. et al. Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer?. Eur Radiol 28, 3059–3065 (2018). https://doi.org/10.1007/s00330-018-5329-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-018-5329-y